Advertisement

Cardiovascular Drugs and Therapy

, Volume 4, Issue 2, pp 451–456 | Cite as

Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol

  • Terje R. Pedersen
  • Michael Kantor
New Calcium Antagonists

Summary

Treatment with nisoldipine (2×10 mg tablets once daily) and nifedipine (2×10 mg capsules three times daily) in patients with severe, but stable effort angina pretreated with atenolol (100 mg once daily in 19 patients and 50 mg once daily in one patient) were compared for their effects on bicycle exercise tolerance and their adverse effects in a randomized 2×4 week, double-blind, double-dummy crossover study. All patients had multivessel disease, 16 patients had occlusion of at least one vessel, and eight patients had a history of myocardial infarction. Two patients left the study during the initial nisoldipine period, one because of aggravation of the angina and the other because of suspected allergic reaction. Addition of nifedipine to atenolol treatment significantly improved the variables measured for severity of angina, such as time of exercise until 1 mm and 2 mm ST-segment depression, total exercise time and total workload. In contrast, no such improvement was noted after the addition of nisoldipine to atenolol. However, nisoldipine resulted in a significant prolongation of the time to the initiation of chest discomfort, the maximum heart rate, and the double product.

In atenolol-treated patients with severe effort angina pectoris, nifedipine 20 mg tid improved exercise capacity, while nisoldipine 20 mg once daily did not have a similar effect.

Key Words

angina pectoris nifedipine nisoldipine atenolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kazda S, Garthoff B, Meyer H, et al. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylate (nisoldipine, BAY K 5552).Arzneim Forsch (Drug Res) 1980;30:2144–2162.Google Scholar
  2. 2.
    Alexander GJ, Dias Souza J, Segal SA, et al. Experimental coronary artery spasm: Prevention by nisoldipine and nifedipine but not by verapamil.Clin Res 1983;31:166a.Google Scholar
  3. 3.
    Kazda S, Garthoff B, Rämsch K-D, et al. Nisoldipine. In: Scriabine A, ed.New drugs annual: Cardiovascular drugs. New York: Raven Press, 1983;243–257.Google Scholar
  4. 4.
    Brügmann U, Blasini R, Rudolph W. Analysis of extent and duration of the antiischemic effects of nisoldipine: Results of a double-blind, randomized, crossover, placebo-controlled, acute and long-term study.Eur Heart J 1984;5(Suppl 1):274.Google Scholar
  5. 5.
    Warltier DC, Meils CM, Gross GJ, et al. Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay K 5552), a new dihydropyridine calcium antagonist.J Pharmacol Exp Ther 1981;218:296–302.PubMedGoogle Scholar
  6. 6.
    Vogt A, Neuholds KL, Krenzer H. Hemodynamic effects of the new vasodilator drug Bay K 5552 in man.Arzneim Forsch 1980;30:2162–2164.Google Scholar
  7. 7.
    Maxwell GH, Crompton S, Renics V. Effect of nisoldipine upon the general and coronary hemodynamics of the anesthetized dog.J Cardiovasc Pharmacol 1982;4:393–397.PubMedGoogle Scholar
  8. 8.
    Warltier D, Zyvoloski M, Gross G, et al. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: Systemic and coronary hemodynamics with and without combined beta adrenergic blockade.J Pharmacol Exp Ther 1984;230:367–375.PubMedGoogle Scholar
  9. 9.
    Lichtelen PR, Engel HJ, Raffenbeul W. Calcium entry blockers, especially nifedipine, in angina of effort: Possible mechanisms and clinical implications. In: Opie LH, ed.Calcium antagonists and cardiovascular disease. New York: Raven Press, 1984:221–236.Google Scholar
  10. 10.
    Schipke JD, Burkhoff D, Alexander J, et al. Effect of nisoldipine on the contractile state of the isolated canine left ventricle.Cardiovasc Drugs Ther 1987;1:287.Google Scholar
  11. 11.
    Lam J, Chaitman BR, Crean P, et al. A dose-ranging, placebo-controlled, double-blind trial of nisoldipine in effort angina: Duration and extent of antianginal effect.J Am Coll Cardiol 1985;6:447–452.PubMedGoogle Scholar
  12. 12.
    Reicher-Reiss H, Vered Z, Goldbourt H, et al. Efficacy of nisoldipine compared to nifedipine in chronic stable angina.Cardiovas Drugs Ther 1987;1:279.Google Scholar
  13. 13.
    Prager G, Weiss K-H, Schmitz H. Efficacy of nisoldipine on myocardial ischemia during 24-hour ECG-monitoring.Cardiovasc Drugs Ther 1987;1:277.Google Scholar
  14. 14.
    Schulz. Antianginal effectiveness of the calcium antagonist nifedipine depending on the type of coronary disease.Z Kardiol 1983;72:657–664.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Terje R. Pedersen
    • 1
  • Michael Kantor
    • 2
  1. 1.Cardiology DepartmentAker SykehusOslo 5Norway
  2. 2.Bayer (Sverige) ABStockholmSweden

Personalised recommendations